|
1
|
Dembo AJ: Radiotherapeutic management of
ovarian cancer. Semin Oncol. 11:238–250. 1984.PubMed/NCBI
|
|
2
|
Einhorn N, Tropé C, Ridderheim M, Boman K,
Sorbe B and Cavallin-Ståhl E: A systematic overview of radiation
therapy effects in ovarian cancer. Acta Oncol. 42:562–566. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Thomas GM and Dembo AJ: Integrating
radiation therapy into the management of ovarian cancer. Cancer.
71(Suppl 4): 1710–1718. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Martinez A, Schray MF, Howes AE and
Bagshaw MA: Postoperative radiation therapy for epithelial ovarian
cancer: the curative role based on a 24-year experience. J Clin
Oncol. 3:901–911. 1985.PubMed/NCBI
|
|
5
|
Cardenes H and Randall ME: Integrating
radiation therapy in the curative management of ovarian cancer:
current issues and future directions. Semin Radiat Oncol. 10:61–70.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Albuquerque KV, Singla R, Potkul RK, et
al: Impact of tumor volume-directed involved field radiation
therapy integrated in the management of recurrent ovarian cancer.
Gynecol Oncol. 96:701–704. 2005.
|
|
7
|
May LF, Belinson JL and Roland TA:
Palliative benefit of radiation therapy in advanced ovarian cancer.
Gynecol Oncol. 37:408–411. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Fujiwara K, Suzuki S, Yoden E, Ishikawa H,
Imajo Y and Kohno I: Local radiation therapy for localized relapsed
or refractory ovarian cancer patients with or without symptoms
after chemotherapy. Int J Gynecol Cancer. 12:250–256. 2002.
View Article : Google Scholar
|
|
9
|
Swenerton KD, Santos JL, Gilks CB, et al:
Histotype predicts the curative potential of radiotherapy: the
example of ovarian cancers. Ann Oncol. 22:341–347. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Thomas G: Revisiting the role of radiation
treatment for non-serous subtypes of epithelial ovarian cancer. In:
American Society of Clinical Oncology Educational Book/ASCO.
American Society of Clinical Oncology Meeting; pp. e205Toronto.
2013, PubMed/NCBI
|
|
11
|
Brown AP, Jhingran J, Klopp AH, Schmeler
KM, Ramirez PT and Eifel PJ: Involved-field radiation therapy for
locoregionally recurrent ovarian cancer. Gynecol Oncol.
130:300–305. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Sklar MD: Increased resistance to
cis-diamminedichloroplatinum(II) in NIH 3T3 cells transformed by
ras oncogenes. Cancer Res. 48:793–797. 1988.PubMed/NCBI
|
|
13
|
Sklar MD: The ras oncogenes increase the
intrinsic resistance of NIH 3T3 cells to ionizing radiation.
Science. 239:645–647. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Rose PG, Bundy BN, Watkins EB, et al:
Concurrent cisplatin-based radiotherapy and chemotherapy for
locally advanced cervical cancer. N Engl J Med. 340:1144–1153.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Sehouli J, Runnebaum IB, Fotopoulou C, et
al: A randomized phase III adjuvant study in high-risk cervical
cancer: simultaneous radiochemotherapy with cisplatin (S-RC) versus
systemic paclitaxel and carboplatin followed by percutaneous
radiation (PC-R): a NOGGO-AGO Intergroup Study. Ann Oncol.
23:2259–2264. 2012. View Article : Google Scholar
|
|
16
|
Quinn M, Avall-Lundqvist E, du Bois A, et
al: History, scope and methodology of the 3rd international
consensus workshop on ovarian cancer 2004. Ann Oncol. 16(Suppl 8):
viii5–viii6. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
WHO Handbook for Reporting Results of
Cancer Treatment. WHO Offset Publication no. 48. World Health
Organization; Geneva: 1979
|
|
18
|
Mayr NA, Taoka T, Yuh WT, Denning LM, Zhen
WK, Paulino AC, et al: Method and timing of tumor volume
measurement for outcome prediction in cervical cancer using
magnetic resonance imaging. Int J Radiat Oncol Biol Phys. 52:14–22.
2002.PubMed/NCBI
|
|
19
|
Kaplan EL and Meier P: Nonparametric
estimation from incomplete observations. J Am Stat Assoc.
53:457–481. 1958. View Article : Google Scholar
|
|
20
|
Cox DR: Regression models and life-tables
(with discussion). J Royal Stat Soc, Series B. 34:187–220.
1972.
|
|
21
|
Agresti A: Categorical Data Analysis. John
Wiley & Sons; New York, NY: 1990
|
|
22
|
Lee SW, Park SM, Kim YM, Kim YS, Choi EK,
Kim DY, et al: Radiation therapy is a treatment to be considered
for recurrent epithelial ovarian cancer after chemotherapy. Tumori.
97:590–595. 2011.PubMed/NCBI
|
|
23
|
Choan E, Quon M, Gallant V and Samant R:
Effective palliative radiotherapy for symptomatic recurrent or
residual ovarian cancer. Gynecol Oncol. 102:204–209. 2006.
View Article : Google Scholar : PubMed/NCBI
|
